Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Minimal Residual Disease: early-phase trial registry
4 of 9 indexed Minimal Residual Disease trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,916 of 28,707 conditions by registered trial count.
9 US clinical trials · 4 currently recruiting · #1,916 of 28,707 conditions by registered trial count
Minimal Residual Disease: 9 US clinical trials tracked, 4 recruiting.
Minimal Residual Disease is the subject of 9 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 3 of these trials.
Enrollment posture brief
Registry condition minimal-residual-disease
OPEN 4 | RECR 44% | LATE 0 | EARLY 7 | RANK #1916 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Acute Ischemic Stroke (44% recruiting · 27 trials)
Minimal Residual Disease lists 4 open slots (44% of 9 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Minimal Residual Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Minimal Residual Disease is recruiting below its size-band peers.
4 of 9 indexed trials (44.4%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Minimal Residual Disease research.
M.D. Anderson Cancer Center accounts for 3 of 9 trials (33.3%). 6 distinct sponsors appear on at least one study for this condition label.
-
Most Minimal Residual Disease trials plan to enrol fewer than 100 people.
Median target enrolment is 40 among the 9 trials that report a genuine target (sentinel values excluded). 7 of those (77.8%) plan for fewer than 100 participants.
-
Minimal Residual Disease research is mostly interventional.
7 interventional and 2 observational studies make up this index (77.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
9 total, page 1 of 1
Caris Biorepository Research Protocol
Caris Science
NCT01499394
CtDNA Based MRD Testing for NAC Monitoring in TNBC
Personalis
NCT06230185
Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)
M.D. Anderson Cancer Center
NCT06358430
A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
M.D. Anderson Cancer Center
NCT07136077
CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies
Stanford University
NCT03233854
Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease
ECOG-ACRIN Cancer Research Group
NCT03516279
Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
Roswell Park Cancer Institute
NCT03192397
Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults w/ Recurrent or Refractory B Cell Malignancies
Stanford University
NCT03241940
Synthetic Vaccine in Patients With Chronic Myeloid Leukemia and Minimal Residual Disease
M.D. Anderson Cancer Center
NCT00267085
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Minimal Residual Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Minimal Residual Disease trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Minimal Residual Disease page
9 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 Minimal Residual Disease trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Minimal Residual Disease trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Minimal Residual Disease condition card totals 9 registered trials; most-linked intervention Fludarabine Phosphate; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.